Frontlight ResearchEarly access
CompletedNo phase
Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry
Key facts
- Who runs it
- Mclean Hospital
- Where
- Belmont, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 32 people enrolled
- Started
- 1 Aug 2021
- Ended
- 15 Aug 2024
- Type of study
- Observational
- Treatments tested
- Marihuana
- BID2 Instrument - breathalyzer
- Record updated
- 2 May 2025
Who can take part
- Age
- 21 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Capable of understanding and complying with the protocol
- In good physical and mental health (normal physical exam, ECG, blood and urine chemistries
- Absence of history or laboratory evidence of diabetes)
- Body Mass Index between 18-30,
- Inclusive Age 21-50 years (age will be verified by driver's license or other valid form of identification)
- Have a stable living situation with current postal address
Who cannot take part
- Concurrent diagnosis of Axis 1 disorder be maintained on an antipsychotic or antidepressant medication
- Meets criteria for current alcohol or substance use disorders (Past alcohol or substance use disorders greater than 3 years ago is acceptable)
- Taking prescription medications except certain short-term anti-fungal agents and some topical creams for dermal condition
- History of major head trauma resulting in cognitive impairment or history of seizure disorder
- Has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT)> 3x the upper limit of normal
- Heavy alcohol drinkers (greater than 15 drinks per week)
- Tobacco use greater than 5 cigarettes per day
- Heavy caffeine use (greater than 500 mg on a regular daily basis)
- For female participants, a positive pregnancy test
Where in United States
- McLean HospitalBelmont, United States
About the trial
What the trial wants to find out
This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.
The group in the trial
- Exhaled Breath Samples
Quantitative detection of marijuana, morphine or fentanyl through exhaled breath
Treatment: Marihuana and BID2 Instrument - breathalyzer
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 2 May 2025